Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HSP990 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| once weekly dosing schedule | EXPERIMENTAL | - |
| twice weekly dosing schedule | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HSP990 | DRUG | - |
Inclusion Criteria: 1. Patients with histologically confirmed, advanced malignant solid tumors whose disease has progressed on standard therapy or for whom no standard therapy exists 2. All patients must have at least one measurable lesion as defined by RECIST. Irradiated lesions are only evaluable...
HSP990 is an investigational small molecule being studied for the treatment of advanced solid malignancies. It is administered by mouth and is intended for adult patients with advanced solid tumors. The drug is currently in clinical development, having completed a Phase 1 trial.
HSP990 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is an investigational oncology therapy in early-stage clinical development.
HSP990 is in Phase 1 of clinical development. A Phase 1 study of the drug has been completed, and it remains an investigational agent. It has not been approved by regulatory authorities and is still undergoing evaluation for safety and tolerability.
HSP990 has been studied in one clinical trial, identified as NCT00879905. This Phase 1 study, titled "A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors," enrolled 64 participants and has been completed. The trial was conducted in Canada, France, and Spain.
The clinical trial of HSP990, NCT00879905, was a controlled study. It was not randomized and not double-blind. The trial enrolled adult patients aged 18 years and older of all sexes, and it did not include healthy volunteers.